Q-Med terminates collaboration agreement with Medy-Tox
The collaboration comprised the development and commercialization of new products based on botulium toxin and potential for Q-Med to distribute Medy-Tox’s existing botulinum toxin type A product. The
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.